ARTESUNATE is a malaria treatment that uses an artemisinin derivative. It is preferable over quinine as an intravenous form for severe malaria. It is frequently used in conjunction with mefloquine as part of a combination treatment. The use of artesunate is not suggested for malaria prophylaxis.

SIDE-EFFECTS

Headaches, nausea, bradycardia, stomach pain, body aches, vomiting, dizziness, and diarrhea are some of the most prevalent side effects.

WARNINGS AND PRECAUTIONS

• Due to the potential for hepatotoxic consequences, patients with hepatic impairment should be given special attention.
• Delaying treatment for severe malaria during pregnancy may result in substantial morbidity and mortality for both the mother and the fetus.
• Following treatment with artesunate 120 mg injection, patients should be informed that they must finish the necessary oral antimalarial therapy.
• Patients should be informed that regular blood tests are required for the 4-week period following treatment completion in order to check for post-treatment delayed hemolysis.
• Renal function, hyperglycemia, and hepatic/hematological function should all be evaluated throughout treatment. Signs of toxicity, such as neurological problems and chronic vomiting/rash, should be observed.